Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca FluMist Supply Jumps With CDC's Seal Of Approval

Executive Summary

US FDA's approval kept very limited amounts available the past two flu seasons; 2.7 million doses to be shipped for the 2018-2019 season.

You may also be interested in...



FluMist Rejuvenated With CDC Advisory Panel Endorsement; Effectiveness Data Still To Come

US panel votes 12 to 2 to recommend use of nasal vaccine, which has been reformulated to include a new influenza A strain.

FDA Supports FluMist Use, Releases Lots For 2016 Flu Season

Despite a CDC advisory committee recommendation that FluMist not be used in the forthcoming influenza season, FDA says the benefits of the nasal formulation outweigh any potential risks.

US FDA Puts Spotlight On Alkermes' Violative Vivitrol Ad

The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.

Topics

Related Companies

UsernamePublicRestriction

Register

PS123945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel